



No association between long-chain *n*-3 fatty acid intake during pregnancy and risk of type 1 diabetes in offspring in two large Scandinavian pregnancy cohorts

Nicolai A. Lund-Blix¹ · Anne A. Bjerregaard^{2,3} · German Tapia¹ · Ketil Størdal^{1,4,5} · Anne Lise Brantsæter¹ · Marin Strøm^{2,6} · Thorhallur I. Halldorsson^{2,7} · Charlotta Granström² · Jannet Svensson^{8,9} · Geir Joner^{4,5} · Torild Skriverhaug^{4,5} · Pål R. Njølstad^{10,11} · Sjurður F. Olsen^{2,6,12,13} · Lars C. Stene¹

Received: 12 January 2024 / Accepted: 20 February 2024 / Published online: 19 March 2024
© The Author(s) 2024

Abstract

Aims/hypothesis The aim of this study was to investigate whether higher dietary intake of marine *n*-3 fatty acids during pregnancy is associated with a lower risk of type 1 diabetes in children.

Methods The Danish National Birth Cohort (DNBC) and the Norwegian Mother, Father and Child Cohort Study (MoBa) together include 153,843 mother–child pairs with prospectively collected data on eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) intake during pregnancy from validated food frequency questionnaires. Type 1 diabetes diagnosis in children ($n=634$) was ascertained from national diabetes registries.

Results There was no association between the sum of EPA and DHA intake during pregnancy and risk of type 1 diabetes in offspring (pooled HR per g/day of intake: 1.00, 95% CI 0.88, 1.14), with consistent results for both the MoBa and the DNBC. Robustness analyses gave very similar results.

Conclusions/interpretation Initiation of a trial of EPA and DHA during pregnancy to prevent type 1 diabetes in offspring should not be prioritised.

Keywords Child health · Cohort studies · Human · Intrauterine nutrition · Maternal and child health · Nutrition · Pregnancy · Type 1 diabetes

Nicolai A. Lund-Blix and Anne A. Bjerregaard are joint first authors.

Sjurður F. Olsen and Lars C. Stene are joint senior authors.

✉ Lars C. Stene
lars.christian.stene@fhi.no

¹ Norwegian Institute of Public Health, Oslo, Norway

² Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

³ Centre for Clinical Research and Prevention, Copenhagen University Hospitals – Bispebjerg and Frederiksberg, Frederiksberg, Denmark

⁴ Faculty of Medicine, Division of Paediatric and Adolescent Medicine, University of Oslo, Oslo, Norway

⁵ Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway

⁶ University of the Faroe Islands, Torshavn, Faroe Islands

⁷ Faculty of Food Science and Nutrition, University of Iceland, Reykjavik, Iceland

⁸ Steno Diabetes Center Copenhagen, Copenhagen, Denmark

⁹ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

¹⁰ Mohn Research Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway

¹¹ Children and Youth Clinic, Haukeland University Hospital, Bergen, Norway

¹² Department of Public Health, University of Copenhagen, Copenhagen, Denmark

¹³ Harvard TH Chan School of Public Health, Boston, MA, USA

Research in context

What is already known about this subject?

- Long-chain marine *n*-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) have anti-inflammatory effects
- Maternal DHA and EPA supplementation during pregnancy has been shown in a randomised trial to reduce the risk of asthma in children
- Animal studies and retrospective human studies have suggested a protective effect of marine *n*-3 fatty acid intake in pregnancy on autoimmune type 1 diabetes risk reduction in offspring

What is the key question?

- Are higher intakes of long-chain marine *n*-3 fatty acids (EPA and DHA) in the maternal diet during pregnancy associated with a lower risk of childhood-onset type 1 diabetes?

What are the new findings?

- This joint analysis of two of the world's largest pregnancy cohorts with complete follow-up of more than 150,000 children for type 1 diabetes showed a robust and precise lack of association between maternal EPA and DHA intake and risk of type 1 diabetes in children

How might this impact on clinical practice in the foreseeable future?

- Initiation of a trial of EPA and DHA during pregnancy to prevent type 1 diabetes in offspring should not be prioritised

Abbreviations

DHA	Docosahexaenoic acid
DNBC	Danish National Birth Cohort
EPA	Eicosapentaenoic acid
FFQ	Food frequency questionnaire
MoBa	Norwegian Mother, Father and Child Cohort Study

Introduction

Long-chain marine *n*-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) have anti-inflammatory effects [1] and may influence the development of type 1 diabetes [2]. Studies in experimental animals and retrospective case–control studies have reported associations between early life exposure to *n*-3 fatty acids and lower risk of type 1 diabetes [3]. Furthermore, associations between childhood intake of dietary fatty acids and risk of islet autoimmunity or type 1 diabetes have been reported for high-risk cohorts, although these results were only suggestive for EPA and DHA [2, 4, 5].

DPA, EPA and other fatty acids cross the placenta [6], and maternal dietary intake of these fatty acids during pregnancy may influence offspring physiology and health [7]. Notably, in a randomised trial of a fish oil supplement (containing EPA and DHA) taken from the second trimester of pregnancy, there was a reduction in the risk of asthma or wheezing in children

at age 5 years compared with placebo [8], providing proof of concept that maternal DPA and DHA can influence offspring risk of an immune-mediated disease. Few prospective studies have investigated maternal intake of marine *n*-3 fatty acids in relation to risk of childhood-onset type 1 diabetes [9].

We aimed to investigate whether higher intakes of the long-chain marine *n*-3 fatty acids (EPA and DHA) in the maternal diet during pregnancy are associated with a lower risk of childhood-onset type 1 diabetes in two of the largest pregnancy cohorts in the world.

Methods

Participants and design The Danish National Birth Cohort (DNBC) recruited pregnant women from 1996 to 2002 (last birth in 2003) and the Norwegian Mother, Father and Child Cohort Study (MoBa) recruited pregnant women from 1999 to 2008 (last birth in 2009) throughout the respective countries, with 35% and 41% of eligible women participating in the two studies, respectively [10, 11] (see electronic supplementary material [ESM] Methods for further details). Both cohorts are based on written consent and received ethical approval (see ESM Methods).

Dietary exposure data Dietary intake was assessed during pregnancy using validated harmonised food frequency questionnaires (FFQs). In the DNBC, women were recruited

during their first antenatal visit to a general practitioner (gestational week ~6), whereas, in the MoBa, pregnant women received an invitation letter prior to their first ultrasound examination in gestational week ~18. Participants from the DNBC included in this study were women who answered an FFQ in mid-pregnancy and participated in two telephone interviews on behavioural factors and health in gestational weeks 12 and 30. The MoBa participants who were included in this study were women who answered a questionnaire on behavioural factors and health in gestational week ~15 and an FFQ in week 22. The MoBa FFQ was introduced from 2002, so data from women recruited before this were excluded from the current analysis (see ESM Methods for further details of the FFQs). The two cohorts together included 153,843 mother–child pairs with data on maternal intake of EPA and DHA (Fig. 1).

Outcome: type 1 diabetes We ascertained the date of type 1 diabetes diagnosis for offspring from national childhood diabetes registries (excluding monogenic and type 2 diabetes) (see ESM Methods for further details). Data on offspring were not stratified by sex.

Statistical analysis We used time from birth to type 1 diabetes diagnosis in Cox regression analyses, using the sum of EPA and DHA intake from food and supplements during pregnancy as a continuous variable in the primary analyses (estimating HRs per gram per day of intake). Based on the a priori

statistical analysis plan the following covariates were included in adjusted models: maternal parity, maternal pre-pregnancy BMI, maternal smoking during pregnancy (never/sometimes/daily), maternal type 1 diabetes, offspring sex, duration of breastfeeding, and maternal education level (see ESM Methods for details of covariates). We pooled the adjusted regression results from the two cohorts using a random-effects meta-analysis (see ESM Methods for further details).

Results

Among 153,843 children, 634 (0.41%) developed type 1 diabetes during follow-up. The median (IQR) total maternal intake of EPA and DHA together during pregnancy was 0.26 g/day (0.15–0.44) for the DNBC and 0.56 g/day (0.32–1.07) for the MoBa, with a higher intake of fish and a much larger proportion of users of fish oil supplements in Norway (68%) than in Denmark (3.6%; ESM Table 1). Of the women, 46–48% were nulliparous, 9–14% smoked during pregnancy and 68–77% had a pre-pregnancy BMI <25 kg/m² (ESM Table 2).

There was no association between the sum of EPA and DHA intake during pregnancy and offspring risk of type 1 diabetes (HR 1.00, 95% CI 0.88, 1.14) after adjustment for maternal parity, maternal pre-pregnancy BMI, maternal smoking during pregnancy, maternal type 1 diabetes, offspring sex, duration of breastfeeding, and maternal education level; Fig. 2).




Fig. 1 Flow chart of generation of the analysis sample. Total number of mother–child pairs included in the analysis: 153,843 ($n=634$ of whom developed type 1 diabetes during follow-up)




Fig. 2 Maternal intake of EPA and DHA during pregnancy and risk of type 1 diabetes in children in the DNBC and MoBa pregnancy cohorts ($n=153,843$ mother–child pairs, of whom $n=634$ children developed type 1 diabetes). HRs per g/day of intake of the sum of EPA and DHA from foods and supplements were adjusted for mater-

nal parity, maternal pre-pregnancy BMI, maternal smoking during pregnancy, maternal type 1 diabetes, offspring sex, duration of breastfeeding, and maternal education level. The p value in the plot is for Cochran's Q test for heterogeneity of the HR between the MoBa and the DNBC. DL, DerSimonian and Laird random-effects meta-analysis

Robustness analyses, including adjustment for additional variables such as maternal vitamin D intake, also supported this conclusion (ESM Table 3). In addition, there was no deviation from linearity or any sign of a threshold effect in categorical analyses; adjusted HRs comparing the upper to the lower quintile of the sum of EPA and DHA intake were 1.19 (95% CI 0.81, 1.74) for the DNBC and 0.84 (0.58, 1.23) for the MoBa (ESM Table 3). Furthermore, secondary analyses showed no association between intake of fish, or the common dietary 18-carbon chain $n-3$ fatty acid alpha-linolenic acid, in pregnancy and risk of type 1 diabetes in offspring (ESM Table 3).

Discussion

This study found a complete lack of association between EPA and DHA intake during pregnancy and risk of type 1 diabetes; these data were consistent between the DNBC and the MoBa, with relatively narrow 95% CIs.

Our results are consistent with data from a birth cohort with high genetic risk for type 1 diabetes from Finland [9]. Our results therefore confirm and extend this lack of association in larger, general population cohorts. Although not investigating fatty acids directly, another cohort study including children at high genetic risk for type 1 diabetes found no association between maternal fish intake and risk of type 1 diabetes in offspring [12].

The major strengths of our study include the very large, population-based cohorts from two different countries and prospectively collected exposure data during pregnancy, and the complete follow-up of type 1 diabetes diagnosis using nationwide registries. Limitations include the lack of biomarkers of exposure and the low numbers of non-European participants. Below we discuss the strengths and limitations in more detail.

Our cohorts were population based and assessed dietary intake, including dietary supplements, during pregnancy.

Biomarker data on EPA and DHA intake were not available in our study; however, the ability of the FFQ to quantify $n-3$ fatty acid intake has been validated against biomarkers in both cohorts [13, 14]. In addition, a nested case–control prospective study from Norway found no association between offspring type 1 diabetes and EPA and DHA levels in the phospholipid fraction of maternal serum collected in late pregnancy [15]. While biomarkers are not influenced by recall and self-report, they are not without problems. Storage and handling of samples may lead to oxidation. Furthermore, biomarkers may be influenced by fasting or recent meals, as well as genetic and other factors regulating metabolism of fatty acids, depending on the type of specimen and assay methods used [16]. Common variants in the fatty acid desaturase (*FADS1/FADS2/FADS3*) gene cluster are associated with a lower efficiency of conversion of the dietary precursor $n-3$ fatty acid alpha-linolenic acid to EPA and DHA and lower blood levels of EPA and DHA [1]. In the asthma prevention trial cited in the introduction, both lower baseline blood levels of EPA and DHA and a genetic variant associated with lower blood levels of these fatty acids were associated with a stronger relative effect of fish oil supplementation on the prevention of asthma [8]. On the other hand, studies of other disease outcomes in adults have not found consistent interactions between intake of EPA or DHA and genetic variants in the *FADS* gene cluster with regard to cardiometabolic disease outcomes [1]. Future studies of maternal $n-3$ fatty acid intake in pregnancy in relation to childhood type 1 diabetes could consider including genetic variants in the *FADS* gene cluster influencing conversion of alpha-linolenic acid to EPA and DHA.

We cannot exclude the possibility that higher intakes of EPA and DHA than those observed in our studies may show an association with type 1 diabetes. However, analysis of quintiles of the sum of EPA and DHA intake did not suggest any threshold effect. We adjusted for intake of vitamin D in pregnancy in

robustness analyses, even though previous evidence suggests no association with type 1 diabetes [17]. Unmeasured confounding, for instance from toxicants in fatty fish, may have influenced our results; however, there is currently no strong evidence supporting an association between such toxicants and type 1 diabetes [2] and we do not believe that toxicants have confounded our results substantially. Given the largely Scandinavian origin of our participants, we believe that our results are generalisable to other European-origin populations, but not necessarily to populations with large proportions of people of other ancestries. Finally, our results do not exclude a potential effect of EPA and DHA intake in children rather than in their pregnant mothers.

In conclusion, the hypothesis that a higher maternal *n*-3 fatty acid intake during pregnancy reduces the risk of type 1 diabetes in offspring was not supported by this study. In a setting where primary prevention trials are extremely expensive and time-consuming [18], we believe that our results, together with the evidence discussed above, clearly indicate that a trial of EPA and DHA during pregnancy to prevent type 1 diabetes in offspring should not be prioritised.

Supplementary Information The online version contains peer-reviewed but unedited supplementary material available at <https://doi.org/10.1007/s00125-024-06125-4>.

Acknowledgements We are grateful to all the participating families in Denmark and Norway for taking part in these ongoing cohort studies.

Funding Open access funding provided by Norwegian Institute of Public Health (FHI). The DNBC is supported by the March of Dimes Birth Defects Foundation, the Danish Heart Association, the Danish National Research Foundation, the Danish Pharmaceutical Association, the Danish Ministry of Health, the National Board of Health and the Innovation Fund Denmark (grant 09-067124). The MoBa is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. PRN was supported by the European Research Council (AdG no. 293574), Stiftelsen Trond Mohn Foundation (Mohn Research Center of Diabetes Precision Medicine), the Research Council of Norway (FRIPRO grant no. 240413), the Western Norway Regional Health Authority (Strategic Fund 'Personalised Medicine for Children and Adults') and the Novo Nordisk Foundation (grant no. 54741). The substudy on type 1 diabetes in the DNBC was funded by the European Foundation for the Study of Diabetes (EFSD)/JDRF/Lilly Programme. The substudy on type 1 diabetes in the MoBa was funded by the Research Council of Norway (grant no. 2210909/F20) and the European Union Horizon 2020 research and innovation programme under grant agreement no. 874864 HEDIMED.

Data availability Computer codes for the statistical analyses and aggregated data are available from the corresponding author on request. The consent given by participants in the two cohorts does not provide for storage of individual-level data in repositories or journals. Access to individual-level data sets from the MoBa database requires an application, approval from the Regional Committee for Medical and Health Research Ethics in Norway, and an agreement with MoBa and the endpoint registries, which can be obtained by applying at <https://helsedata.no/en/> (for more information, see the MoBa website, <https://www.fhi.no/en/ch/studies/moba/>, or email Mor.BarnData@fhi.no). Data from the DNBC used in this study are managed by the DNBC Secretariat at Statens Serum Institut in Copenhagen, Denmark, and can be made available to researchers on approval from the DNBC organisation, com-

pliance with the EU General Data Protection Regulation (GDPR) and approval from the data owner (Statens Serum Institut). Researchers who wish to apply for access to datasets for replication purposes should do so through the DNBC Secretariat (see <https://www.dnbc.dk>). Access to datasets requires approval from the local data protection agency (in a Danish context; 'Fortegnelsen') at the researcher's institution and an agreement with the DNBC at Statens Serum Institut.

Authors' relationships and activities JS serves as an adviser to Medtronic and Novo Nordisk. She owns shares in Novo Nordisk and has received fees for speaking on behalf of Medtronic, Sanofi Aventis, Rubin Medical and Novo Nordisk. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement SFO, LCS and NAL-B conceptualised the study. NAL-B and LCS drafted the protocol and a detailed analysis plan with input from SFO, AAB, MS, TIH, CG, GT, KS and ALB. SFO, TIH and CG were responsible for the dietary database for the DNBC, and ALB was responsible for the dietary database for the MoBa. JS (DNBC) and TS, PRN and GJ (MoBa) were responsible for type 1 diabetes case validation and the diabetes registries. TIH and AAB carried out the statistical analyses of DNBC data, and NAL-B and LCS carried out the statistical analyses of the MoBa data and the meta-analyses. KS and GT contributed to data linkage and preparation, including data cleaning and categorisation of MoBa data. NAL-B and LCS drafted the manuscript with input from all authors. SFO and LCS had primary responsibility for the final content. All authors read and approved the final version for publication. LCS and SFO are guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Schulze MB, Minihane AM, Saleh RNM, Riserus U (2020) Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases. *Lancet Diabetes Endocrinol* 8(11):915–930. [https://doi.org/10.1016/S2213-8587\(20\)30148-0](https://doi.org/10.1016/S2213-8587(20)30148-0)
- Norris JM, Johnson RK, Stene LC (2020) Type 1 diabetes-early life origins and changing epidemiology. *Lancet Diabetes Endocrinol* 8(3):226–238. [https://doi.org/10.1016/S2213-8587\(19\)30412-7](https://doi.org/10.1016/S2213-8587(19)30412-7)
- Johansen VBI, Josefsen K, Antvorskov JC (2023) The impact of dietary factors during pregnancy on the development of islet autoimmunity and type 1 diabetes: a systematic literature review. *Nutrients* 15(20):4333. <https://doi.org/10.3390/nu15204333>
- Norris JM, Yin X, Lamb MM et al (2007) Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at

- increased risk for type 1 diabetes. *JAMA* 298(12):1420–1428. <https://doi.org/10.1001/jama.298.12.1420>
5. Niinistö S, Takkinen HM, Erlund I et al (2017) Fatty acid status in infancy is associated with the risk of type 1 diabetes-associated autoimmunity. *Diabetologia* 60(7):1223–1233. <https://doi.org/10.1007/s00125-017-4280-9>
 6. Lewis RM, Childs CE, Calder PC (2018) New perspectives on placental fatty acid transfer. *Prostaglandins Leukot Essent Fatty Acids* 138:24–29. <https://doi.org/10.1016/j.plefa.2018.10.001>
 7. Middleton P, Gomersall JC, Gould JF, Shepherd E, Olsen SF, Makrides M (2018) Omega-3 fatty acid addition during pregnancy. *Cochrane Database Syst Rev* 11(11):CD003402. <https://doi.org/10.1002/14651858.CD003402.pub3>
 8. Bisgaard H, Stokholm J, Chawes BL et al (2016) Fish oil-derived fatty acids in pregnancy and wheeze and asthma in offspring. *N Engl J Med* 375(26):2530–2539. <https://doi.org/10.1056/NEJMo a1503734>
 9. Niinistö S, Takkinen HM, Uusitalo L et al (2014) Maternal dietary fatty acid intake during pregnancy and the risk of preclinical and clinical type 1 diabetes in the offspring. *Br J Nutr* 111(5):895–903. <https://doi.org/10.1017/S0007114513003073>
 10. Olsen J, Melbye M, Olsen SF et al (2001) The Danish National Birth Cohort – its background, structure and aim. *Scand J Public Health* 29(4):300–307. <https://doi.org/10.1177/14034948010290040201>
 11. Magnus P, Birke C, Vejrup K et al (2016) Cohort profile update: the Norwegian mother and child cohort study (MoBa). *Int J Epidemiol* 45(2):382–388. <https://doi.org/10.1093/ije/dyw029>
 12. Johnson RK, Tamura R, Frank N et al (2021) Maternal food consumption during late pregnancy and offspring risk of islet autoimmunity and type 1 diabetes. *Diabetologia* 64(7):1604–1612. <https://doi.org/10.1007/s00125-021-05446-y>
 13. Mikkelsen TB, Osler M, Olsen SF (2006) Validity of protein, retinol, folic acid and n-3 fatty acid intakes estimated from the food-frequency questionnaire used in the Danish National Birth Cohort. *Public Health Nutr* 9(6):771–778. <https://doi.org/10.1079/PHN2005883>
 14. Brantsæter AL, Haugen M, Hagve TA et al (2007) Self-reported dietary supplement use is confirmed by biological markers in the Norwegian Mother and Child Cohort Study (MoBa). *Ann Nutr Metab* 51(2):146–154. <https://doi.org/10.1159/000103275>
 15. Sørensen IM, Joner G, Jenum PA, Eskild A, Stene LC (2012) Serum long chain n-3 fatty acids (EPA and DHA) in the pregnant mother are independent of risk of type 1 diabetes in the offspring. *Diabetes Metab Res Rev* 28(5):431–438. <https://doi.org/10.1002/dmrr.2293>
 16. Arab L, Akbar J (2002) Biomarkers and the measurement of fatty acids. *Public Health Nutr* 5(6A):865–871. <https://doi.org/10.1079/PHN2002391>
 17. Thorsen SU, Mårild K, Olsen SF et al (2018) Lack of association between maternal or neonatal vitamin D status and risk of childhood type 1 diabetes: a Scandinavian case-cohort study. *Am J Epidemiol* 187(6):1174–1181. <https://doi.org/10.1093/aje/kwx361>
 18. Knip M, Writing Group for the TRIGR Study Group (2018) Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial. *JAMA* 319(1):38–48. <https://doi.org/10.1001/jama.2017.19826>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.